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Acute lung injury (ALI) causes significant morbidity and mortality.
Fibroproliferation in ALI results in worse outcomes, but the mech-
anisms governing fibroproliferation remain poorly understood.
Regulatory T cells (Tregs) are important in lung injury resolution.
Their role infibroproliferation is unknown.We sought to identify the
role of Tregs in ALI fibroproliferation, using a murine model of lung
injury. Wild-type (WT) and lymphocyte-deficient Rag-12/2 mice re-
ceived intratracheal LPS. Fibroproliferationwascharacterizedbyhis-
tology and themeasurement of lung collagen. Lung fibrocytes were
measuredby flow cytometry. Todissect the role of Tregs in fibropro-
liferation, Rag-12/2 mice received CD41CD251 (Tregs) or CD41
CD252 Tcells (non-Tregs) at the time of LPS injury. To define the
role of the chemokine (C-X-C motif) ligand 12 (CXCL12)–CXCR4
pathway in ALI fibroproliferation, Rag-12/2 mice were treated with
the CXCR4 antagonist AMD3100 to block fibrocyte recruitment.
WT and Rag-12/2 mice demonstrated significant collagen deposi-
tion onDay 3 after LPS.WTmice exhibited the clearance of collagen,
but Rag-12/2 mice developed persistent fibrosis. This fibrosis was
mediated by the sustained epithelial expression of CXCL12 (or
stromal cell-derived factor 1 [SDF-1]) that led to increased fibrocyte
recruitment. The adoptive transfer of Tregs resolved fibroprolifera-
tion by decreasing CXCL12 expression and subsequent fibrocyte re-
cruitment. Blockade of the CXCL12–CXCR4 axis with AMD3100 also
decreased lung fibrocytes and fibroproliferation. These results indi-
cate a central role for Tregs in the resolutionof ALI fibroproliferation
by reducing fibrocyte recruitment along the CXCL12–CXCR4 axis.
A dissection of the role of Tregs in ALI fibroproliferationmay inform
the design of new therapeutic tools for patients with ALI.
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Acute lung injury (ALI) and acute respiratory distress syn-
drome (ARDS) affect 190,000 individuals in the United States
each year, accounting for 75,000 deaths (1). The only treatment
that improves outcomes involves a lung-protective strategy in
patients on mechanical ventilation (2). Mortality from ALI/ARDS
remains ashigh as 44%(3).
ALI/ARDS is divided into an exudative phase marked by
edema fluid, hyaline membrane formation, and neutrophilic in-
filtration, followed in some patients by a fibroproliferative phase
(4). Fibroproliferation is part of the normal repair response, and
is characterized by the intra-alveolar accumulation of fibroblasts
and collagen deposition. If this process is ineffective or continues
unabated, patients may develop fibrosis (5). Longer durations of
ARDS correspond to increased lung collagen and fibrosis, and
portend worse outcomes (6). Fibroproliferative changes on bi-
opsy and computed tomography predict mortality (7, 8). The
determinants of prolonged fibroproliferation and factors that
govern its resolution remain poorly understood.
The fibroblast is a key cell in fibroproliferation (9). The
source of activated fibroblasts (myofibroblasts) in ALI remains
unclear. Three cell populations likely contribute: (1) resident
lung fibroblasts (10), (2) epithelial cells that transform into myo-
fibroblasts via epithelial-to-mesenchymal transition (11), and
(3) bone marrow progenitors called fibrocytes. Fibrocytes are
identified by their expression of CD45, collagen-1 (Col-1), and
CXCR4 (12–14). In a model of bleomycin fibrosis, fibrocytes
accounted for 20% of myofibroblasts (10, 15). Fibrocytes are
contained in the bronchoalveolar lavage (BAL) and blood of
patients with idiopathic pulmonary fibrosis (IPF), and may pre-
dict exacerbations (14, 16). Recently, fibrocytes were found in
the BAL of patients with ARDS, and were associated with
increased mortality (17, 18). The mechanisms governing fibro-
cyte recruitment and activation in ALI remain unknown.
Persistent inflammation is a hallmark of fibroproliferative
ARDS (4). Our group has highlighted a central role for regula-
tory T cells (Tregs, i.e., CD41CD251Foxp31 T cells) in the
resolution of lung inflammation (19). The role of Tregs in the
fibroproliferative response to ALI has not been described, to
the best of our knowledge.
Using a well-establishedmodel of lung injury involving intratra-
cheal LPS (20), we show that lymphocyte-deficient Rag-12/2 mice
demonstrate persistent fibroproliferation, characterized by sus-
tained fibrocyte recruitment to the lung. The adoptive transfer
of Tregs, but not other CD41 T cells, into Rag-12/2 mice reduces
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CLINICAL RELEVANCE
Fibroproliferation in the context of acute lung injury (ALI)
leads to worse outcomes, but the factors that underlie the
fibroproliferative phase of ALI remain unknown. We have
shown that regulatory T cells reduce fibroproliferation after
LPS-induced ALI by reducing fibrocyte recruitment to the
lung along the CXCL12–CXCR4 axis. This may lead to the
development of novel diagnostic and therapeutic strategies
for patients with ALI.
 
fibrocyte number and resolves fibroproliferation. This fibrocyte
reduction is caused by a Treg-mediated decrease in lung CXCL12,
a chemokine that induces fibrocyte recruitment. Epithelial cells
are an important source of CXCL12, suggesting that Tregs reduce
CXCL12 concentrations by interacting with the epithelium. The
blockade of CXCR4, the receptor for CXCL12, decreases fibro-
cyte numbers and fibroproliferation in Rag-12/2 mice, providing
further evidence for the importance of the CXCL12–CXCR4
axis in ALI fibroproliferation. Our results indicate that Tregs
play a critical role in the fibroproliferative response to ALI, and
that targeting the CXCL12–CXCR4 pathway may provide new
insights into the treatment of fibroproliferative ARDS.




C57BL/6 wild-type (WT) and Rag-12/2 mice (aged 6–8 wk) were
purchased from Jackson Laboratories (Bar Harbor, ME). Green-
fluorescent protein (GFP)-labeled, Foxp31 mice were the gift of
Alexander Rudensky (Sloan-Kettering Institute, New York, NY).
Protocols were approved by the Johns Hopkins Animal Care and
Use Committee (Baltimore, MD).
Preparation of Mice
Mice were anesthetizedwith intraperitoneal ketamine and acetylproma-
zine (150 and 13.5 mg/kg, respectively) before tracheal exposure.
Escherichia coli LPS (3.75 mg/g, O55:B5 L2880; Sigma-Aldrich, St.
Louis, MO) or sterile water was instilled intratracheally via 20-gauge
catheter. Animals were killed by vena cava exsanguination (19).
CXCR4 Blockade
Rag-12/2 mice underwent daily intraperitoneal injections of AMD3100
(200 mg/250 ml PBS; Sigma-Aldrich) or PBS (250 ml).
Isolation and Adoptive Transfer of Tregs
CD41CD251 and CD41CD252 T cells were isolated from GFP-
Foxp31 spleens using magnetic beads (Miltenyi, Cambridge, MA)
(19). Single-cell suspensions (1 3 106 cells in 100 ml PBS) were trans-
ferred within 60 minutes after LPS by retro-orbital injection. Treg
purity was measured at 85–90% by flow cytometry.
Analysis of BAL Fluid
Two aliquots of 0.7 ml PBS were instilled into the right lung. Cell counts
were determined by hemocytometer. Protein was measured using the
method of Lowry (19).
Lung Histology and Immunohistochemistry
Left lungs were inflated to 25 cm H2O with 1% low-melting agarose
(Invitrogen, Grand Island, NY) (19) for evaluation by Masson’s tri-
chrome. Sections were prepared for immunohistochemistry with
anti–SDF-1 AB (1/50, clone 79018; R&D Systems, Minneapolis, MN),
followed by a mouse-on-mouse immunodetection technique (Vector
Laboratories, Burlingame, CA), peroxidase-conjugated secondary
antibody, and development with 3,3-diaminobenzidine.
Lung and BAL Collagen Content
Left lungs were frozen in liquid nitrogen. Lungs were homogenized in
1ml of Complete Lysis Buffer (Roche, Indianapolis, IN), using anUltra-
Turrax tissue homogenizer (Janke and Kunkel, Wilmington, NC). Col-
lagen was measured by Sircol Assay (BioColor, Carrickfergus, UK),
according to the manufacturer’s instructions.
Lung CXCL12 Concentrations
CXCL12 concentrations were measured in lung homogenates, using an
ELISA duoset (R&D Systems).
Preparation of Lung Homogenates for Flow Cytometry
Right lungs were excised, minced, and incubated at 378C in RPMI
containing 2.4 mg/ml collagenase I and 20 mg/ml DNase (Invitrogen),
and then mashed through a 70-mm nylon strainer (BD Biosciences,
San Jose, CA). For epithelial cell isolation, lungs were instilled with
1.2 ml Dispase (BD Biosciences), with 3 U/ml elastase (Worthington,
Lakewood, NJ) at removal. Red blood cells were removed using ACK
lysis buffer (Invitrogen), and cells were resuspended in FACS buffer.
Flow Cytometry
Cells were prepared for FACS analysis (19). Surface stains included
Alexa-700 conjugated anti-CD4 (Ebioscience, San Diego, CA),
allophycocyanin-conjugated (APC) anti-CXCR4 (BD Biosciences),
APC-Cy7–conjugated anti-CD326, and biotinylated anti-CD45 and
CD31 with V450-conjugated streptavidin secondary (Biolegend, San Diego,
CA). Intracellular stains included biotinylated rabbit anti–Col-I
Figure 1. Adoptive transfer of T regulatory cells (Tregs;
CD41CD251 cells) but not CD41CD252 cells into Rag-
12/2 mice restored normal resolution of lung injury. (A)
Survival curves after intratracheal LPS for all groups (*P ¼
0.021 by survival log-rank, and #P ¼ 0.024 by x2 test, n >
14 in all groups). (B) Weight loss presented as percentage
of baseline weight after intratracheal LPS for all groups
(*P , 0.001, and #P , 0.001, n > 14, all groups). (C)
Bronchoalveolar lavage (BAL) cell counts on Day 3 and
Day 7 after intratracheal LPS or intratracheal water for all
groups (*P ¼ 0.012 and #P , 0.05, n . 4, all groups). (D)
BAL protein measured by the method of Lowry on Day 3
and Day 7 after intratracheal LPS or intratracheal water for
all groups (*P ¼ 0.001 and #P ¼ 0.006, n > 4 all groups).
AT, adoptive transfer; WT, wild-type.
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antibody (Rockland Chemicals, Gilbertsville, PA) with a PE–Texas
red–conjugated streptavidin secondary (BD Biosciences) and APC-
conjugated anti-CXCL12 (R&D Systems).
Statistical Analysis
Mortality was analyzed by x2 test. Markers of injury were compared
using the Student t test or Mann-Whitney rank sum test. Multiple
groups were compared using one-way ANOVA or one-way ANOVA
on ranks. Pairwise comparisons were performed using the Student t test
with the Bonferroni correction or the Dunn test. Lung CXCL12 was
compared with fibrocyte numbers, using linear regression analysis on
log-transformed data. Statistical analysis was performed using Sigma-
plot 11.0 (Systat Software, Inc., Chicago, IL).
Further details on adoptive transfers, FACS, the Sircol assay, ELISA,
and immunohistochemistry are provided in the online supplement.
RESULTS
Resolution of LPS-Induced Lung Injury Was Impaired
in Lymphocyte-Deficient Mice
After the administration of intratracheal LPS, Rag-12/2 mice
demonstrated increased mortality when compared with WT mice
(Figure 1A). Both WT and Rag-12/2 mice lost body weight, but
WT mice returned to near-baseline body weight by Day 7,
whereas Rag-12/2 mice demonstrated persistently decreased body
weight (Figure 1B). Both WT and Rag-12/2 mice exhibited sim-
ilar degrees of lung injury on Day 3, as indicated by BAL cell
count (Figure 1C) and protein (Figure 1D). Both BAL cell counts
and protein returned to near baseline values by Day 7 in WT
mice, whereas these remained elevated in Rag-12/2 mice (Figures
1C and 1D).
Figure 2. Adoptive transfer of Tregs reduced
fibroproliferation in Rag-12/2 mice after LPS in-
jury. (A) Lung sections were stained with Mas-
son’s trichrome to highlight collagen deposition
on Day 3 and Day 7 after intratracheal LPS or
intratracheal water in WT and Rag-12/2 mice (n>
3 in each group; images are of representative
examples,3200magnification). (B) Lung sections
were stained with Masson’s trichrome on Day 7
after intratracheal LPS or intratracheal water in
Rag-12/2 mice, Rag-12/2 mice 1 Tregs, and
Rag-12/2 mice 1 non-Tregs (images are of repre-
sentative examples,3200 magnification, n> 3 in
each group). (C) Lung collagen was measured by
Sircol assay in all groups on Day 3 and Day 7 after
intratracheal LPS (*P¼ 0.009 and #P¼ 0.047, n>
4, all groups). (D) BAL collagen was measured by
Sircol assay in all groups on Day 3, Day 7, and
Day 10 after intratracheal LPS (*P ¼ 0.002, yP ¼
0.003, zP ¼ 0.005, and #P ¼ 0.005, n > 3, all
groups). (E) Lung collagen was positively corre-
lated with the natural log of BAL collagen (r ¼
0.73, P , 0.001, using Pearson product moment
correlation).
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Adoptive Transfer of Tregs Restored Normal Resolution
of Lung Injury
After magnetic bead isolation, Tregs (CD41CD251 cells; 90%
Foxp31) or non-Tregs (CD41CD252 cells) were adoptively
transferred into intratracheal LPS–exposed Rag-12/2 mice.
The adoptive transfer of Tregs but not non-Tregs into Rag-
12/2 mice 1 hour after intratracheal LPS restored the normal
resolution of lung injury, as evidenced by significantly im-
proved mortality, increased body weight, and decreased
markers of lung injury (Figure 1). Adoptive transfer was con-
firmed using flow cytometry to identify Tregs (CD41Foxp31
cells) or non-Tregs (CD41Foxp32 cells) in the BAL, lungs,
and spleens of Rag-12/2 mice (see Figure E1 in the online
supplement). These results confirm the critical role of Tregs
in the normal resolution of LPS-induced lung injury, and es-
tablish the pattern of responses against which all other param-
eters are compared.
LPS-Induced Fibroproliferation Resolved in the Presence
of Tregs
We assessed fibroproliferation by histology as well as by measur-
ing collagen concentrations in the BAL and lungs of WT mice,
Rag-12/2 mice, and Rag-12/2 mice that received Tregs or non-
Treg CD41 cells. Collagen deposition and interstitial thickening
were evident in both WT and Rag-12/2 mice on Day 3 after LPS
injury. However, histologic changes resolved in WT mice by
Day 7, whereasRag-12/2 mice demonstrated persistent interstitial
thickening and collagen deposition (Figure 2A). The adop-
tive transfer (AT) of Tregs but not non-Tregs into Rag-12/2
mice led to the histopathologic resolution of fibroproliferation
(Figure 2B). Lung collagen concentrations (using the Sircol
assay) increased in both WT and Rag-12/2 mice on Day 3,
but remained persistently elevated in Rag-12/2 mice on Day 7
after LPS injury (Figure 2C). The AT of Tregs into Rag-12/2
mice reduced lung collagen concentrations to baseline by Day 7.
Lung collagen remained significantly elevated in mice receiving
non-Tregs, compared with both WT mice and mice that re-
ceived Tregs. We also examined BAL fluid to see if collagen
concentrations were altered in the alveolar compartment. WT
and Rag-12/2 mice exhibited increased collagen in BAL fluid on
Day 3 after LPS injury (Figure 2D). BAL collagen concentra-
tions returned to baseline in WT mice, but remained elevated in
Rag-12/2 mice up to Day 10 after LPS injury, compared with
WT mice. The AT of Tregs, but not non-Tregs, into Rag-12/2
mice returned BAL collagen concentrations to baseline. BAL
collagen was positively correlated with lung collagen, suggesting
that fibroproliferation as measured in the alveolar compartment
reflects overall lung fibroproliferation (r ¼ 0.73, P , 0.001 by
Pearson product moment correlation; Figure 2E). These data
strongly support a vital role for Tregs in the resolution of fibro-
proliferation after LPS injury.
Tregs Reduced Lung and BAL Fibrocyte Number after ALI
Fibrocytes are circulating progenitor cells that can be recruited
to sites of injury to become collagen-producing myofibroblasts.
Fibrocytes can be identified according to the expression of the
surface markers CD45 and CXCR4, and the intracellular expres-
sion of collagen-1 (Col-I) (12, 13) (Figure E2A). Using flow
cytometry, we measured fibrocyte numbers in the lungs (Figure
3A) and BAL (Figure 3B) of WT and Rag-12/2 mice after LPS
injury. Despite similar increases in both lung and BAL fibro-
cytes on Day 3 after LPS injury, fibrocytes were persistently
elevated in Rag-12/2 mice compared with WT mice on Day 7.
The AT of Tregs, but not non-Tregs, into Rag-12/2 mice returned
both lung and BAL fibrocytes to WT concentrations. These results
suggest that one of the mechanisms by which Tregs resolve fibro-
proliferation after LPS injury occurs through a reduction in lung
fibrocyte number.
Epithelial-Derived CXCL12 Led to Fibrocyte Recruitment
after LPS Injury
CXCL12 (or stromal cell-derived factor 1 [SDF-1]) is the most
potent ligand for the CXCR4 receptor (expressed on fibrocytes),
and is an important stimulus for fibrocyte recruitment to the lung
after injury (12). We used immunohistochemistry to stain for
CXCL12 in lung sections from WT and Rag-12/2 mice that had
received either intratracheal water or LPS. CXCL12 was in-
creased in both WT and Rag-12/2 mice on Day 3 after lung
injury. On Day 7, CXCL12 returned to near baseline in WT
mice, but Rag-12/2 mice demonstrated persistently elevated
CXCL12 expression. At higher magnifications, epithelial cells
appeared to comprise the predominant cell type that stained
positive for CXCL12 after LPS injury (Figure 4A).
To confirm that epithelial cells were the major source of
CXCL12 expression after LPS injury, we used multicolor flow
cytometry to characterize intracellular CXCL12 expression in var-
ious cell populations in both WT and Rag-12/2 mice on Day 7
after LPS injury. We used biotinylated CD31 and CD45 antibod-
ies with a V450-conjugated streptavidin to distinguish endothelial
cells (CD311) and leukocytes (CD451) from other cell populations.
Figure 3. Fibrocytes were initially increased after LPS injury, and were
reduced in the presence of Tregs. (A) Lung fibrocyte number was de-
termined using flow cytometry to identify CD451Col-11CXCR41 cells
in lung single-cell suspensions in all groups on Day 3 and Day 7 after
intratracheal LPS (*P ¼ 0.007 and #P ¼ 0.017, n > 6, all groups). (B)
BAL fibrocyte number was determined using flow cytometry to identify
CD451Col-11CXCR41 cells in BAL single-cell suspensions on Day 3 and
Day 7 after intratracheal LPS (*P , 0.05 and #P , 0.05, n > 4, all
groups).
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CD31(2)CD45(2) cells exhibited a fourfold higher level of ex-
pression of CXCL12 by mean fluorescence intensity, suggesting
that leukocytes and endothelial cells were not important sources
of elevated lung CXCL12 expression after LPS injury (Figure 4B).
Further examination of the CD31(2)CD45(2) cells revealed
that the subset of cells that stained positive for the pan-epithelial
marker, CD326, demonstrated a 22-fold higher level of CXCL12
expression compared with CD326-cells (Figure 4C). CD326, or
epithelial cell adhesion molecule (EpCAM), was recently used
to characterize human lung epithelial cell subsets (22). This pro-
vides strong evidence that epithelial cells were the primary
source of the increased CXCL12 expression after LPS injury.
Tregs Reduced Lung CXCL12 Concentrations after
LPS Injury
To better quantify CXCL12 expression and to determine the role
of Tregs in the regulation of CXCL12 after LPS injury, we mea-
sured lung CXCL12 concentrations by ELISA in WTmice, Rag-
12/2 mice, and Rag-12/2 mice that received Tregs and non-Treg
CD41 lymphocytes. CXCL12 concentrations predicted lung
fibrocyte numbers according to linear regression analysis (r ¼
0.91, R2 ¼ 0.84, P , 0.001; Figure 5A), consistent with the
established role of CXCL12 as a chemokine for fibrocyte
recruitment.
CXCL12 concentrations were significantly increased in both
Rag-12/2 and WT mice on Day 3 after LPS injury (Figure 5B).
CXCL12 concentrations returned to baseline by Day 7 in WT
mice, but remained significantly elevated in Rag-12/2 mice. The
AT of Tregs into Rag-12/2 mice reduced CXCL12 concentra-
tions to baseline. The AT of non-Tregs into Rag-12/2 mice led
to a slight reduction in CXCL12 concentrations, but CXCL12
remained significantly elevated compared with the Rag-12/2
control (92% higher), WT Day 7 LPS (80% higher), and AT
Treg groups (45% higher). These data suggest that Tregs re-
duced the epithelial expression of CXCL12 after LPS injury,
leading to decreased fibrocyte recruitment and the resolution
of fibroproliferation.
Blockade of the CXCR4 Receptor with AMD3100 Decreased
Fibroproliferation by Reducing Fibrocyte Recruitment
to the Lung
To better understand the role of the CXCL12–CXCR4 axis in
ALI fibroproliferation, we used the chemical AMD3100
to block the CXCR4 receptor. AMD3100 is a nonpeptide
Figure 4. Epithelial cells were an
important source of CXCL12 af-
ter LPS-induced lung injury. (A)
Lung sections were stained for
CXCL12 by immunohistochem-
istry on Day 3 and Day 7 after
intratracheal LPS. Epithelial cells
(arrows) appeared to be the pre-
dominant source of CXCL12
staining (images are of represen-
tative examples, 3200 magnifi-
cation, n > 2 mice in each
group; inset, 3400 magnifica-
tion). (B) Single-cell suspensions
were prepared from the lungs of
WT and Rag-12/2 mice on Day 7
after intratracheal LPS or sterile
water. Cells were stained with
biotinylated anti-CD31 and
anti-CD45, followed by V450-
conjugated streptavidin as well
as allophycocyanin-conjugated
(APC)–Cy7–conjugated anti-
CD326. Cells were fixed, per-
meabilized, and stained with
APC-conjugated anti-CXCL12.
Cells were gated for CD31 and
CD45 positivity, and CXCL12
expression was examined by
mean fluorescence intensity
(MFI) (*P , 0.001, n ¼ 16
mice). (C) CD312CD452 cells
were gated for CD326 (epi-
thelial cell adhesion molecule
[EpCAM]) expression to iden-
tify epithelial cells. CXCL12
expression in CD3261 and
CD3262 cells was examined by
MFI (*P , 0.001, n ¼ 16 mice).
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antagonist of CXCR4 that inhibits the binding and function of
CXCL12 with high affinity and specificity (23, 24). Rag-12/2
mice received intratracheal LPS on Day 0, followed by daily
intraperitoneal injections of either AMD3100 (200 mg in
250 ml) or sterile PBS (250 ml), starting on Day 0. Mortality was
no different between Rag-12/2 mice that received AMD3100
and Rag-12/2 mice that received PBS (25% and 27%, respec-
tively). Peak weight loss was measured at nearly 25% of initial
body weight in both groups, and was similar to the peak weight
loss observed in WT and Rag-12/2 mice that received LPS alone
(Figure 6A). BAL protein and cell counts were not significantly
different between groups (Figure E4). In Rag-12/2 mice, CXCR4
receptor blockade with AMD3100 decreased lung fibrocytes
(Figure 6B), histologic fibrosis (Figure 6C), and lung collagen
(Figure 6D) on Day 7 after intratracheal LPS. Lung CXCL12
concentrations were no different between Rag-12/2 mice that
received AMD3100 or PBS (Figure 6E), indicating that the
difference in fibrocyte numbers between groups was attribut-
able to the CXCR4 receptor blockade rather than a decrease
in CXCL12 expression. WT animals receiving intratracheal LPS
and daily injections of AMD3100 did not exhibit reduced
inflammation on Day 4 after lung injury, as measured by BAL
protein (Figure E4A) and cell count (Figure E4B), demonstrating
that AMD3100 does not markedly alter the inflammatory re-
sponse to LPS. These results provide further evidence that
fibrocytes recruited along the CXCL12–CXCR4 axis play an
important role in fibroproliferation after LPS injury, because
blocking CXCR4 reduces fibrocyte numbers, collagen deposi-
tion, and fibrosis in Rag-12/2 mice.
DISCUSSION
Fibroproliferation is part of the normal repair response to ALI
(5). This repair begins early, as evidenced by increased markers
of collagen turnover in the BAL fluid of patients with ARDS
within the first days of diagnosis (25, 26). However, excessive
fibroproliferation is associated with worse outcomes, because
patients develop decreased lung compliance and increased dead
space, and require prolonged mechanical ventilation (4, 6, 8).
Despite its importance to patient outcomes, the factors that
underlie fibroproliferation in ALI remain poorly understood.
Tregs down-regulate lung inflammation in a number of contexts
(27–30). Because the fibroproliferative phase of ARDS is charac-
terized by persistent interstitial inflammation (4), Tregs might be
expected to reduce fibroproliferation, perhaps by dampening the
inflammation that leads to myofibroblast accumulation and col-
lagen deposition (31). Patients with IPF and collagen vascular
disease–associated pulmonary fibrosis demonstrate a reduced
number and function of Tregs in BAL fluid and peripheral
blood, compared with controls, suggesting that Tregs may play
a role in fibroproliferation (27). However, conflicting data in the
literature have emerged regarding Tregs in animal models of
pulmonary fibrosis (31–34), suggesting that the role of Tregs in
regulating fibroproliferation may be both context-specific and
site-specific. To our knowledge, the role of Tregs in the fibro-
proliferative response to ALI has not been described.
Our data support a novel role for Tregs in accelerating the res-
olution of fibroproliferation by decreasing fibrocyte recruitment
to the lung after injury. Fibrocytes are CD451Col-11CXCR41
bone marrow–derived cells that migrate to sites of injury to
become collagen-producing myofibroblasts (12, 13). Fibrocytes
play an important role in bleomycin models of pulmonary fibro-
sis (10, 15). They are present in the BAL fluid and blood of
patients with IPF, and increased fibrocyte numbers predict
exacerbations (14, 16). Fibrocytes are also found in the BAL
fluid of patients with ARDS, and are associated with increased
mortality (17, 18).
CXCL12 is constitutively expressed in a number of tissues, and
binds to the CXCR4 receptor on fibrocytes to promote migration
(12, 14, 35–37). The significant association between lung CXCL12
concentrations and fibrocyte numbers in our model supports pre-
vious studies that demonstrated the importance of CXCL12 in
fibrocyte recruitment (12, 13). CXCL12 secretion is induced in
rat Type II epithelial cells after scratch injury, implicating the
epithelium as an important source of CXCL12 (38). In patients
with IPF, epithelial cells expressed CXCL12 at higher concentra-
tions than in control samples (14). Epithelial CXCL12 increases in
both murine and human lungs after ALI (39). Our data indicate
that CD3261 epithelial cells are the most abundant source of
CXCL12 expression after LPS-induced ALI.
Our study shows that Tregs facilitate the resolution of ALI
fibroproliferation by decreasing lung CXCL12 concentrations,
leading to a reduction in lung fibrocytes and a decrease in col-
lagen deposition and fibrosis. Tregs might alter lung CXCL12
concentrations in a number of ways. Because epithelial cells
are themost abundant source of CXCL12 after LPS injury, Tregs
likely modulate epithelial CXCL12 expression. Treg–epithelial
interactions were previously described. For example, crosstalk
between Tregs and the intestinal or retinal epithelium is an
Figure 5. Adoptive transfer of Tregs reduced lung CXCL12 concentra-
tions. CXCL12 concentrations were measured in whole-lung homoge-
nates by ELISA. (A) CXCL12 concentrations were positively correlated
with the natural log of lung fibrocyte numbers (r ¼ 0.91, R2 ¼ 0.84, P,
0.001, using linear regression on log-transformed data; n ¼ 9 total
mice where CXCL12 concentrations and lung fibrocyte numbers were
available from the same time point: 5 Rag-12/2 AT non-Tregs, 3 Rag-
12/2 AT-Tregs, and 1 WT Day 7 LPS). (B) CXCL12 concentrations were
determined by ELISA on whole-lung homogenates on Day 3 and day 7
after intratracheal LPS (*P , 0.001, #P , 0.001, yP ¼ 0.009, ¥P ¼ 0.01,
and zP ¼ 0.036, n > 4, all groups).
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important determinant of both immune tolerance and Treg pro-
liferation (40–42). Type II alveolar epithelial cells (AECs) can
present antigen to naive Tcells through the Class II major his-
tocompatibility complex (MHC), and induce the proliferation
of Tregs, in part through a transforming growth factor (TGF)–
b–dependent mechanism (43). In the context of our model,
Tregs might down-regulate AEC CXCL12 expression in a con-
tact-dependent manner. For example, the engagement of Class
II MHC receptors on epithelial cells by Tregs might lead to
a change in CXCL12 expression. Furthermore, a contact-
independent interaction might occur between Tregs and AECs,
perhaps through the release of cytokines that decrease
AEC CXCL12 production. Tregs may also exert their effects
on AECs through a third cell type. For example, our group
has shown that Tregs decrease the macrophage production of
TNF-a in a contact-dependent manner (19). An alteration in
macrophage phenotype might then lead to a decrease in AEC
CXCL12 production. Future experiments will seek to identify
the specific interactions between Tregs and epithelial cells that
govern overall CXCL12 expression and subsequent fibrocyte
recruitment in the context of ALI.
The reduction in lung collagen concentrations and fibrocytes in
Rag-12/2 mice after CXCR4 receptor blockade with AMD3100
provides further evidence that the CXCL12–CXCR4 axis is crit-
ical in fibrocyte-mediated ALI fibroproliferation, and is consistent
with previous studies that demonstrated a reduction in lung fibro-
sis in bleomycin models after CXCR4 or CXCL12 blockade (12,
24). The lack of a significant difference in BAL cell count, protein,
and lung CXCL12 concentrations between AMD3100-treated
Rag-12/2 mice and PBS control mice, as well as the similar peak
weight loss in each group, indicate that the difference in fibropro-
liferation did not result from reduced inflammation after LPS in-
jury, and was instead attributable to the decrease in fibrocyte
number. The uncoupling of inflammation and fibroproliferation
in this context further supports the notion that the reduction in
fibroproliferation seen in our Treg AT experiments was not solely
the result of a Treg-dependent decrease in inflammation, but was
in part attributable to a reduction in fibrocyte recruitment. Given
the potential difficulties of using Tregs as therapy for human au-
toimmune and inflammatory diseases (44), the pharmacologic ma-
nipulation of downstream pathways such as the CXCL12–CXCR4
axis may provide attractive targets for ALI treatment in the future.
Factors in addition to fibrocyte recruitment along the CXCL12–
CXCR4 axis likely modulate fibrocyte numbers and subsequent
fibroproliferation in the context of ALI. For example, Tregs could
influence both fibrocyte proliferation and survival. Moreover, fibro-
cyte number alone clearly does not explain the differences in lung
collagen concentrations seen between our experimental groups, as
evidenced by the finding that lung fibrocytes were lower in WT
mice on Day 7 after LPS compared with water control mice, yet
lung collagen concentrations were slightly higher in the Day 7 WT
mice. The collagen-producing capacity of fibrocytes likely depends
in part on their surrounding environment. In addition, our flow
cytometry markers may not have identified fibrocytes as they tran-
sitioned to a myofibroblast phenotype. In culture, fibrocytes lose
the expression of CD34 and CD45 as they transition to a collagen-
producing cell (45), making them potentially difficult to track once
they transition to a myofibroblast phenotype in vivo. Future
Figure 6. Blockade of the CXCR4 recep-
tor with AMD3100 reduced fibroprolifer-
ation in Rag-12/2 mice by reducing
fibrocyte recruitment to the lung after
LPS injury. (A) Weight loss presented as
percentage of baseline weight after intra-
tracheal LPS for Rag-12/2 mice that re-
ceived intraperitoneal AMD3100 or
intraperitoneal PBS. (B) Lung fibrocyte
number was determined using flow
cytometry to identify CD451Col-11
CXCR41 cells in lung single-cell sus-
pensions in both groups on Day 7 after
intratracheal LPS (*P ¼ 0.001; n > 7, all
groups). (C) Lung sections were stained
with Masson’s trichrome to highlight col-
lagen deposition on Day 7 after intratra-
cheal LPS in both groups (images are of
representative examples; magnification,
3200). (D) Lung collagen was measured
by Sircol assay in both groups on Day 7
after intratracheal LPS (*P ¼ 0.012; n >
5, all groups). (E) CXCL12 concentra-
tions were measured in whole-lung
homogenates by ELISA in both groups
on Day 7 after intratracheal LPS (n > 5,
all groups).
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experiments will seek to examine differences in fibrocyte prolif-
eration, survival, and collagen-producing capacity in the context
of ALI fibroproliferation, and to refine the tracking of fibrocytes
after they transition to a myofibroblast phenotype.
Our study contains other important limitations. Although the pu-
rity of our bead-sorted Tregs used in adoptive transfers was consis-
tently greater than 85%, some CD42CD251 cells were included in
our ATs. Although these represented on average less than 7.5% of
overall transferred cells, they may have contributed to the reduction
in fibroproliferation. In addition to Tregs, CD25 can be expressed
in CD81 T cells, activated B cells, and (at lower concentrations)
monocytes. Almost all of the CD42CD251 cells demonstrated
a low forward and side scatter by flow cytometry, suggesting they
were likely lymphocytes (data not shown). Our group has shown
that the AT of splenocytes fromCD4-depleted spleens intoRag-12/2
mice does not resolve LPS-induced lung injury. Furthermore, the AT
of CD81 lymphocytes into Rag-12/2 mice dose not result in the
resolution of lung injury (19). This suggests that CD42CD251 cells
do not play a role in reducing fibroproliferation in our model. Treg
depletion with the CD25-specific antibody PC61 impairs the resolu-
tion of lung injury, further emphasizing the critical role of Tregs in
our model of lung injury (19).
The small but significant decrease in CXCL12 concentrations
after the AT of non-Tregs into Rag-12/2 mice might suggest that
CD41 lymphocytes other than Tregs play a role in reducing
fibroproliferation. However, this small reduction in CXCL12
did not result in decreased biochemical or histologic markers
of fibroproliferation. The decrease in CXCL12 may also have
been the result of a small number of Tregs present in the non-
Treg ATs, either from bead separation impurities or from the
induction of naive CD41 lymphocytes into Tregs (46). Although
we did not find significant numbers of Tregs in the lungs of Rag-
12/2 mice that received non-Tregs on Day 7 after AT, the num-
ber of Tregs required to reduce CXCL12 concentrations and the
kinetics of this response remain unknown.
Although our study highlighted an important role for fibro-
cytes in ALI fibroproliferation, it did not address the potential
contributions of other cell types to the activated myofibroblast
pool. Resident fibroblasts were shown to be an important source
of collagen deposition and fibrosis in both animal and human
models. Recently an interest has emerged in the concept of
epithelial-to-mesenchymal transition, whereby epithelial cells
may either transform into collagen-producing myofibroblasts
or secrete profibrotic growth factors and cytokines that can lead
to fibroproliferation (10, 47). Future experiments will seek to
define the role of these cell types in our injury model.
In conclusion, we report on a unique role for Tregs in the res-
olution of ALI fibroproliferation through the control of fibrocyte
recruitment to the lung after LPS injury. A better understanding
of the role of Tregs in the fibroproliferative response will poten-
tially uncover pathways that might lead to new diagnostic and
therapeutic options in patients with ALI.
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